Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 90 days matching "oncology"

ResearchPUBMED2 days ago

Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.

Scientists are studying a new type of medicine made from circular RNA, which is RNA shaped like a circle instead of a line. Because of their circular shape, these medicines may stay in the body longer and work better than current RNA medicines. Researchers are testing these circular RNA medicines to treat cancer, immune system diseases, and rare diseases.

WHY IT MATTERSCircular RNA therapeutics could eventually offer longer-lasting treatments for rare diseases with fewer doses needed, but patients should know that claims about safety and effectiveness vary depending on how the medicine is made—there's no one-size-fits-all answer yet.
ℹ Good to knowRead →
ResearchPUBMEDApr 1

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).

Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.

WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
💬 Ask your doctorrare cancersultrarare malignanciesRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases